Prevalence of Weight Gain and Associated Factors Among People Living with HIV 6- and 12-Months Post Dolutegravir-Based Anti-Retroviral Regimen Initiation in Gulu, Uganda; A Hospital-Based Retrospective Cohort Study
{{output}}
Background: Dolutegravir (DTG), an integrase-strand transfer inhibitor approved by WHO in 2019 as part of first-line HIV treatment, has been linked to weight gain; however, data on this and its associated factors remain limited. ... ...
